Skip to main content
. Author manuscript; available in PMC: 2010 May 1.
Published in final edited form as: Nat Biotechnol. 2009 Nov 1;27(11):1025–1031. doi: 10.1038/nbt.1583

Figure 2. Coverage plots of targeted sequences.

Figure 2

For the validation phase (A) base by base coverage of three target sequences selected for their varying lengths and GC% amplified by microdroplet (blue) and traditional (red) PCR. For the scale-up phase (B) the coverage of two targets representing an average and maximum amplicon length sequenced by Illumina GA (green) and Roche 454 (yellow) is shown. At the bottom of each plot the PCR primer positions (grey dumbbells connected by line) are shown. Roche 454 end sequencing of average sized amplicons results in 2-fold higher coverage of middle bases whereas end sequencing of larger amplicons results in middle bases having no coverage.